News
Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...
The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new ...
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...
Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback